Page last updated: 2024-12-11
org 33628
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
Org 33628: a very potent & selective antiprogestagen which behaves as an ovulation inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 146157404 |
| SCHEMBL ID | 21740383 |
| MeSH ID | M0249730 |
Synonyms (2)
| Synonym |
|---|
| org 33628 |
| SCHEMBL21740383 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cycle control is better at low than at high doses of antiprogestin in combination with daily dosing of 4 microg/kg desogestrel." | ( Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Deckers, GH; Hanssen, RG; Hodgen, GD; Hsiu, JG; Kloosterboer, HJ; Rose, UM; Schoonen, WG; Verbost, PM; Williams, RF, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (3)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (40.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||